Here is a great sounding post from "Anthony" this morning
Here is a great sounding post from "Anthony" this morning on the CYDY yahoo finance message board; I really wish that he would post on IH as well:
"A couple of updates. I don't know what is or is not happening with the CNN reporter's potential story. I know she's talked to a lot of people, including Dr. Patterson. We have no control over this. As I noted before, but people are still asking re my actuary friend's meeting with one of our US Senators. He said it was a good meeting, but it was clear, and I don't have ANY issues with this, that they were not going to pressure the FDA under any circumstance. I actually have a conference call with my actuary friend and Dr. Patterson on Monday at 11:30 EST. We are working on a plan to take to one of the major managed care players on a RANTES's susceptibility testing program. We also have a great idea (this was my actuary friend's idea) about how to get some incredible national publicity for Dr. Patterson. Since both Patterson and my friend have "national credentials," they are going to team up on this. We have another idea about how to get to the Federal CV task force through two other people that are close to Pence. I would love to mention who one of these folks is, but I don't think that would be a good idea. He has been on CNBC and Fox this week weighing in that we have to get the country back open. I know both of these folks so once we have the plan in place my role in this is to connect with them via email and drop this idea. That could conceivably happen yet this weekend.
The information my friend and Dr. Patterson want to disseminate is fantastic. We have a plan to do this in one of the most visible public forums out there if we can pull it off. The three of us worked on the first and second drafts last night. It will be a really good mix of science and public health information. Dr. Patterson is so professional - he never lets on anything that might get in the public domain that could jeopardize anything, but he certainly seems confident in this RANTES' theory...."
10
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Cuffless BP Monitoring: Changing the Game for AF and HF Ever thought a finger ring could revolutionize blood pressure monitoring? Well, welcome to the future—Sky Labs' ring-type CART monitor has just rocked the scene at the ESC Congress 2026 in Munich. This isn't sci-fi, folks; it's where health tech meets reality, and it's shaking the very foundations of how we manage...
Continue Reading
EQT's Bold Buyback: Crunching the Numbers Alright, let's peel back the curtain on EQT's latest maneuver—finishing up their share buyback program, all neat and tidy for 2026. They nailed down 707,203 of their own shares just in the first week of September, part of a grand total of 4,368,899 snatched up in the entire effort. That's a whopping SEK 1.448 billion invested in...
Continue Reading
Hyosung's Game-Changing Move in the AI Power Sector Guess what? The AI era's heating up, and it's dragging the power sector along for a wild ride. Hyosung Chairman Hyun-Joon Cho peered into that future and decided it's all-in time for the U.S. power market. With AI and data centers cranking up power demands like never before, those rickety old wires need an upgrade fast....
Continue Reading
Stem Cells: The Next Frontier or Hype? Folks, stem cells are no longer just a sci-fi concept tucked away in lab coats. This sector's set to boom from USD 18.9 billion in 2026 to a whopping USD 32.57 billion by 2031. Yeah, you heard it right, a solid 11.5% compound annual growth rate. Now, whether you're an investor or just keeping your finger on the biotech pulse, there's...
Continue Reading
In the biotech world, there's always a race. Clover Biopharmaceuticals is making strides with their RSV+hMPV vaccine candidate, especially for the elderly. Imagine those big leaps in development—all boosted by recent results from a Phase 2 trial down under in Australia. Key Findings of the Trial Immunogenicity Insights They're not messing around with these findings. The...
Continue Reading
Tailored Hair Loss Solutions by Happy Head Imagine trying to fit a square peg in a round hole. That's what one-size-fits-all approaches often feel like in the world of hair loss treatments. Happy Head, recognized by Consumer365, takes that notion and turns it on its head, offering personalized minoxidil formulations for women. The key word here is personalized. More Than...
Continue Reading
Spotlight on Beazer Homes' Proposed Sale Here's a real head-scratcher for folks in the stock trenches: Beazer Homes USA, Inc. (NYSE: BZH) finds itself under the microscope with Halper Sadeh LLC stirring the pot. You can't make this up—just another day in the world of investor rights and looming litigation. Questions Arise Over Shareholder Gains Halper Sadeh LLC, that...
Continue Reading
Modular Construction's Expanding Footprint Behold Lida Group—a titan in the world of modular construction—taking ambitious strides into the global arena, reaching from the sand dunes of Saudi Arabia to the bustling corridors of the United Nations. If you haven't been paying attention, now's the time to get your head in the game. Their expansion isn't just about...
Continue Reading
Rising Threats and New Solutions in CABP Market Listen up, folks. The community-acquired bacterial pneumonia (CABP) market is set to swell. And why is that? Well, it's got everything to do with a growing disease burden, aging populations, and complications from comorbid conditions. But here's the kicker: antimicrobial resistance is climbing like a cat up a tree, and that...
Continue Reading
UST's Strategic Move Into Automotive's Future Wake up and smell the coffee, because UST is shaking up the automotive scene. They've just pulled off a major play by grabbing a majority stake in Italdesign. If that doesn't scream the next leap forward for the auto world, I don't know what does. UST isn't just buying a company; it's marrying Italdesign's legendary design...
Continue Reading
Top 5 Most Recently Viewed Articles
Precision BioSciences Expands Leadership Team for Growth Precision BioSciences, Inc. (Nasdaq: DTIL), a pioneering clinical-stage gene editing company, has made significant changes to its senior leadership team as it aims to advance its in vivo gene editing programs, including the promising PBGENE-HBV project currently in Phase 1 clinical studies. Strategic Leadership...
Continue Reading
Qualcomm Short Interest Overview Qualcomm (QCOM) has recently reported a significant decrease in its short percent of float, which has dropped by 9.4% since the last report. Currently, there are 21.02 million shares sold short, representing 2.12% of the company's total regular shares available for trading. Based on recent trading volumes, it would take approximately 2.25...
Continue Reading
Simply Good Foods Company Shows Positive Growth Simply Good Foods Company (NASDAQ: SMPL), a leader in the nutrition snack industry, has reported impressive financial results for its fiscal first quarter, ending November 30, 2024. This period marks a significant year-over-year improvement in sales and profitability. Financial Highlights of Q1 2025 Impressive Sales and...
Continue Reading
Denmark's Progressive Stance on Deepfake Technology Denmark is taking a significant step in the realm of digital privacy by updating its copyright laws to safeguard individual rights against deepfake technology. This innovative move allows citizens to have legal ownership of their own faces, voices, and bodies. In a world where AI-generated imitations are becoming...
Continue Reading
Spotlight Biographees: Celebrating Remarkable Achievements The Spotlight Series highlights the impressive resumes and career accomplishments of hand-selected professionals. Marquis Who's Who (MWW), the leading biographical publisher globally, proudly acknowledges a diverse group of professionals recognized in the Spotlight Series for their outstanding contributions. This...
Continue Reading